ArticleJournal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
Retrospective Evaluation of Cryoprecipitate Transfusion in Dogs to Prevent or Treat Hemorrhage: 21 Cases (2009-2023).
Article in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retrospective Evaluation of Cryoprecipitate Transfusion in Dogs to Prevent or Treat Hemorrhage: 21 Cases (2009-2023).Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo report homologous cryoprecipitate transfusions in dogs with hemostatic disorders, hemorrhage, or risk of hemorrhage, and to report adverse reactions associated with these cryoprecipitate transfusions.
designRetrospective case series (July 2009 to July 2023).
settingUniversity teaching hospital. ANIMALS: Twenty-one client-owned dogs with hemostatic disorders, hemorrhage, or risk of procedure-related hemorrhage.
interventionsNone. MEASUREMENTS AND MAIN
resultsAll dogs received homologous cryoprecipitate transfusion. Sixteen dogs had von Willebrand disease (one also had factor XI deficiency); three dogs had hemophilia A; and two dogs had normal concentration of von Willebrand factor and were not diagnosed with any hemostatic disorder. Sixteen dogs also received other blood products and/or hemostatic medications. Twenty-two cryoprecipitate transfusions were administered to 16 dogs before, during, or after surgery; 16 of those 22 transfusions were given to 14 dogs without evidence of hemorrhage but with history of bleeding disorder and/or previous hemorrhage with the aim of preventing hemorrhage. Eight transfusions were given to six dogs to control hemorrhage not associated with surgery. Sixteen dogs (18 transfusions) received cryoprecipitate prepared in-house. Five dogs (12 transfusions) received a commercial lyophilized cryoprecipitate. No dog developed any serious adverse reactions to cryoprecipitate transfusion. All dogs were discharged from the hospital (median, 2 days after cryoprecipitate transfusion [range, 1-25 days]). The benefits of cryoprecipitate transfusion could not be well documented because of the retrospective nature of this study and the concurrent administration of other blood products and/or hemostatic medications to 16 dogs.
conclusionsHomologous cryoprecipitate transfusion appeared to be safe when administered for prevention or treatment of hemorrhage in dogs, but additional studies to assess safety and efficacy are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.